BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23378102)

  • 1. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
    Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
    Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
    Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
    J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer?
    Ceulemans G; Voordeckers M; Farrag A; Verdries D; Storme G; Everaert H
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):938-42. PubMed ID: 20932677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG-PET.
    Hoshikawa H; Kishino T; Nishiyama Y; Yamamoto Y; Yonezaki M; Mori N
    Nucl Med Commun; 2011 Aug; 32(8):684-9. PubMed ID: 21709618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ( 18 ) F-FLT PET and ( 18 ) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers.
    Hoshikawa H; Kishino T; Mori T; Nishiyama Y; Yamamoto Y; Inamoto R; Akiyama K; Mori N
    Acta Otolaryngol; 2012 Dec; 132(12):1347-54. PubMed ID: 22992199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.
    Linecker A; Kermer C; Sulzbacher I; Angelberger P; Kletter K; Dudczak R; Ewers R; Becherer A
    Nuklearmedizin; 2008; 47(2):80-5; quiz N12. PubMed ID: 18392317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
    Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
    Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
    J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.